AI Engines For more Details: Perplexity Kagi Labs You
Pain Relief: Naproxen is commonly used to relieve various types of pain, including headache, toothache, muscle pain, menstrual cramps, back pain, and arthritis pain. It works by reducing the production of prostaglandins, substances in the body that are involved in inflammation and pain.
Inflammation: Naproxen helps to reduce inflammation by inhibiting the activity of cyclooxygenase enzymes (COX-1 and COX-2), which are involved in the production of inflammatory prostaglandins. It is often used to treat inflammatory conditions such as arthritis, bursitis, tendonitis, and gout flare-ups.
Fever: Naproxen can help lower fever by reducing the production of prostaglandins, which play a role in regulating body temperature. It is commonly used to alleviate fever associated with various illnesses and infections.
Osteoarthritis: Naproxen is frequently prescribed to manage symptoms of osteoarthritis, a degenerative joint disease characterized by joint pain, stiffness, and reduced range of motion. It helps reduce pain and inflammation associated with this condition, improving mobility and quality of life for affected individuals.
Rheumatoid Arthritis: Naproxen is also used to treat rheumatoid arthritis, an autoimmune condition characterized by joint inflammation, pain, and stiffness. By reducing inflammation and pain, naproxen helps improve joint function and reduce the progression of the disease.
Ankylosing Spondylitis: Naproxen is commonly prescribed for ankylosing spondylitis, a type of arthritis that primarily affects the spine. It helps alleviate pain, stiffness, and inflammation in the spine and other affected joints, improving mobility and quality of life for individuals with this condition.
Dysmenorrhea: Naproxen is effective in relieving menstrual cramps (dysmenorrhea) by reducing the production of prostaglandins, which are responsible for uterine contractions and pain during menstruation.
Migraine: Naproxen is sometimes used as a preventive or acute treatment for migraine headaches. It can help reduce the severity and duration of migraine attacks when taken at the onset of symptoms.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus casei | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Lactobacillus acidophilus | Reduces |
| species | Lactobacillus crispatus | Reduces |
| species | Lactobacillus gasseri | Reduces |
| species | Lactobacillus helveticus | Reduces |
| species | Lactobacillus jensenii | Reduces |
| species | Lactobacillus johnsonii | Reduces |
| species | Lactobacillus kefiranofaciens | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| Acne | 0.6 | -0.6 | |
| ADHD | 0.8 | 0.6 | 0.33 |
| Age-Related Macular Degeneration and Glaucoma | 0 | 0 | |
| Allergic Rhinitis (Hay Fever) | 0.1 | 1 | -9 |
| Allergies | 1.6 | 2 | -0.25 |
| Allergy to milk products | 0.7 | 0.1 | 6 |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 0.8 | 1.8 | -1.25 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.2 | 1.4 | 0.57 |
| Ankylosing spondylitis | 1.1 | 1.6 | -0.45 |
| Anorexia Nervosa | 0.8 | -0.8 | |
| Antiphospholipid syndrome (APS) | 0.1 | 0.3 | -2 |
| Asthma | 1.2 | 1.8 | -0.5 |
| Atherosclerosis | 0.7 | 0.5 | 0.4 |
| Atrial fibrillation | 1.3 | 0.4 | 2.25 |
| Autism | 4.1 | 3.5 | 0.17 |
| Barrett esophagus cancer | 0.3 | 0.1 | 2 |
| benign prostatic hyperplasia | 0.2 | -0.2 | |
| Biofilm | 0.8 | 0.8 | |
| Bipolar Disorder | 0.1 | 0.5 | -4 |
| Brain Trauma | 0.1 | 1.2 | -11 |
| Cancer (General) | 0.1 | 2.3 | -22 |
| Carcinoma | 0.4 | 0.3 | 0.33 |
| Celiac Disease | 1.7 | 1.8 | -0.06 |
| Cerebral Palsy | 0.7 | 0.2 | 2.5 |
| Chronic Fatigue Syndrome | 1 | 1.8 | -0.8 |
| Chronic Kidney Disease | 0.1 | 0.8 | -7 |
| Chronic Lyme | 0.7 | -0.7 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.1 | 5 |
| Chronic Urticaria (Hives) | 0.3 | 0.9 | -2 |
| Coagulation / Micro clot triggering bacteria | 0.1 | 0.4 | -3 |
| Colorectal Cancer | 0.7 | 0.9 | -0.29 |
| Constipation | 0.3 | 1.2 | -3 |
| Coronary artery disease | 0 | 0.4 | 0 |
| COVID-19 | 3.1 | 3.7 | -0.19 |
| Crohn's Disease | 1.7 | 2.1 | -0.24 |
| cystic fibrosis | 0.2 | -0.2 | |
| d-lactic acidosis (one form of brain fog) | 0.8 | 0.8 | |
| deep vein thrombosis | 0.3 | -0.3 | |
| Depression | 3.7 | 4.2 | -0.14 |
| Dermatomyositis | 0.1 | 0.1 | 0 |
| Eczema | 0.2 | 1.3 | -5.5 |
| Endometriosis | 0.6 | 1.8 | -2 |
| Eosinophilic Esophagitis | 0.1 | 0.2 | -1 |
| Epilepsy | 0.6 | 2 | -2.33 |
| Fibromyalgia | 0.1 | 0.9 | -8 |
| Functional constipation / chronic idiopathic constipation | 0.8 | 2.1 | -1.63 |
| gallstone disease (gsd) | 0.5 | 0.4 | 0.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.4 | 0.25 |
| Generalized anxiety disorder | 0.1 | 0.7 | -6 |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.1 | -0.1 | |
| Graves' disease | 1.3 | 0.1 | 12 |
| Halitosis | 0.3 | 0.1 | 2 |
| Hashimoto's thyroiditis | 0.6 | 0.5 | 0.2 |
| Hidradenitis Suppurativa | 0.2 | 0.2 | 0 |
| High Histamine/low DAO | 1 | 0.7 | 0.43 |
| hypercholesterolemia (High Cholesterol) | 0.1 | 0.6 | -5 |
| hyperglycemia | 0.1 | 1.8 | -17 |
| Hyperlipidemia (High Blood Fats) | 0.4 | 0.8 | -1 |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 1 | 2 | -1 |
| Hypothyroidism | 0.2 | -0.2 | |
| Hypoxia | 0.8 | 0.8 | |
| IgA nephropathy (IgAN) | 1.3 | -1.3 | |
| Inflammatory Bowel Disease | 0.8 | 2.5 | -2.13 |
| Insomnia | 0.9 | 0.1 | 8 |
| Intelligence | 0.1 | 0.1 | |
| Intracranial aneurysms | 0.1 | 0.5 | -4 |
| Irritable Bowel Syndrome | 1.7 | 2.6 | -0.53 |
| Liver Cirrhosis | 1.6 | 2 | -0.25 |
| Long COVID | 2.6 | 3.4 | -0.31 |
| Low bone mineral density | 0.1 | -0.1 | |
| Lung Cancer | 0.3 | 0.9 | -2 |
| Mast Cell Issues / mastitis | 0.1 | 0.4 | -3 |
| ME/CFS with IBS | 0.2 | 0.4 | -1 |
| ME/CFS without IBS | 0.1 | 0.2 | -1 |
| Menopause | 0.4 | 0.4 | |
| Metabolic Syndrome | 1.8 | 3.6 | -1 |
| Mood Disorders | 5.6 | 4.2 | 0.33 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 2.3 | 0.8 | 1.87 |
| Multiple system atrophy (MSA) | 1.5 | 0.2 | 6.5 |
| myasthenia gravis | 0.6 | 0.6 | |
| neuropathic pain | 0.4 | -0.4 | |
| Neuropathy (all types) | 0.9 | 0.9 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.4 | 2.3 | -4.75 |
| NonCeliac Gluten Sensitivity | 0.8 | 0.2 | 3 |
| Obesity | 1.8 | 2.7 | -0.5 |
| obsessive-compulsive disorder | 1.3 | 2 | -0.54 |
| Osteoarthritis | 0.1 | 0.1 | |
| Osteoporosis | 0.8 | 1.4 | -0.75 |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 2.5 | 2.5 | 0 |
| Polycystic ovary syndrome | 0.9 | 1.3 | -0.44 |
| Postural orthostatic tachycardia syndrome | 0.8 | -0.8 | |
| Premenstrual dysphoric disorder | 0.2 | 0.2 | |
| primary biliary cholangitis | 0.1 | -0.1 | |
| Psoriasis | 1.2 | 0.7 | 0.71 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.9 | 2.1 | -0.11 |
| Rosacea | 0.1 | 0.5 | -4 |
| Schizophrenia | 3.1 | 0.3 | 9.33 |
| scoliosis | 0.1 | 0.1 | 0 |
| Sjögren syndrome | 1 | 0.6 | 0.67 |
| Sleep Apnea | 0.3 | 1 | -2.33 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.6 | -1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 1.1 | -10 |
| Stress / posttraumatic stress disorder | 1 | 1.6 | -0.6 |
| Systemic Lupus Erythematosus | 1.2 | 2.1 | -0.75 |
| Tic Disorder | 0.3 | 0.1 | 2 |
| Tourette syndrome | 0.3 | 0.6 | -1 |
| Type 1 Diabetes | 0.7 | 0.9 | -0.29 |
| Type 2 Diabetes | 2 | 3 | -0.5 |
| Ulcerative colitis | 1.3 | 2.6 | -1 |
| Unhealthy Ageing | 2 | 1.3 | 0.54 |
| Vitiligo | 0.2 | 0.5 | -1.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [98.80.143 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [98.80.143 ]
